AEZS vs. CORV, DRRX, LEXX, ACXP, XLO, EYEN, VYNE, FBIO, MRKR, and LPCN
Should you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Correvio Pharma (CORV), DURECT (DRRX), Lexaria Bioscience (LEXX), Acurx Pharmaceuticals (ACXP), Xilio Therapeutics (XLO), Eyenovia (EYEN), VYNE Therapeutics (VYNE), Fortress Biotech (FBIO), Marker Therapeutics (MRKR), and Lipocine (LPCN). These companies are all part of the "medical" sector.
Correvio Pharma (NASDAQ:CORV) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking.
Aeterna Zentaris has a consensus target price of $60.00, suggesting a potential upside of 519.20%. Given Correvio Pharma's higher probable upside, analysts plainly believe Aeterna Zentaris is more favorable than Correvio Pharma.
Correvio Pharma has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.
Correvio Pharma has a net margin of -107.81% compared to Correvio Pharma's net margin of -760.32%. Correvio Pharma's return on equity of -83.45% beat Aeterna Zentaris' return on equity.
Aeterna Zentaris received 337 more outperform votes than Correvio Pharma when rated by MarketBeat users. However, 66.13% of users gave Correvio Pharma an outperform vote while only 62.07% of users gave Aeterna Zentaris an outperform vote.
Aeterna Zentaris has lower revenue, but higher earnings than Correvio Pharma. Aeterna Zentaris is trading at a lower price-to-earnings ratio than Correvio Pharma, indicating that it is currently the more affordable of the two stocks.
7.3% of Correvio Pharma shares are owned by institutional investors. Comparatively, 0.7% of Aeterna Zentaris shares are owned by institutional investors. 0.1% of Aeterna Zentaris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Aeterna Zentaris had 4 more articles in the media than Correvio Pharma. MarketBeat recorded 5 mentions for Aeterna Zentaris and 1 mentions for Correvio Pharma. Correvio Pharma's average media sentiment score of 0.40 beat Aeterna Zentaris' score of 0.00 indicating that Aeterna Zentaris is being referred to more favorably in the news media.
Summary
Aeterna Zentaris beats Correvio Pharma on 11 of the 17 factors compared between the two stocks.
Get Aeterna Zentaris News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AEZS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aeterna Zentaris Competitors List
Related Companies and Tools
